-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] On August 31, there was a change in the pharmaceutical sector of Hong Kong stocks.
Among them, Corning & Jereh Pharmaceutical-B rose by more than 11%.
In addition, WuXi AppTec, BeiGene and other stocks also rose significantly
.
Corning & Jereh Pharma-B rose more than 11% against the market in early trading.
Among them, Corning & Jereh Pharma-B rose more than 11% against the market in early trading
.
As of press time, it rose 9.
39% to HK$21.
20, with a turnover of HK$65.
55 million and a current total market value of 19.
512 billion
.
Not long ago, Corning Jerry Pharmaceutical released its 2021 performance report.
For the six months ended June 30, 2021, the company recorded other income of 22.
5 million yuan, and medium-term R&D expenses increased by 73.
5% year-on-year to 232 million yuan.
The main reasons include: : an increase in the number of ongoing clinical trials; an increase in the scale of clinical studies; the advancement of clinical trials of drug candidates; and an increase in staff costs due to an increase in R&D staff and the grant of options to staff resulting in increased compensation
.
During the reporting period, the company's KN046, KN035 and other drug product pipelines and business operations have made significant progress
.
Ping An Securities released a research report saying that the core products of Corning & Jereh Pharmaceuticals are progressing smoothly, and this year is expected to start the first year of commercialization
.
As the next generation of antibodies, double antibodies are expected to be able to solve some of the problems that are difficult for monoclonal antibodies and small molecules to solve
.
The industry believes that the company is expected to be able to deploy the market in advance and occupy the first-mover advantage
.
Under the good development prospects of the industry in which the company is located, based on the company's rich independent technology platform, there will still be a rich pipeline layout in the future, which is expected to further enhance the company's performance; coupled with the announcement of a number of clinical data in the second half of this year, it will catalyze the company's value Upgrade, Ping An Securities maintained the company's "recommended" rating
.
WuXi PharmaTech's rapid intraday rise On August 31, WuXi PharmaTech rose rapidly intraday, with an increase of more than 2% within 5 minutes.
As of press time, it was reported at 132.
21 yuan, with a turnover of 2.
062 billion and a turnover rate of 0.
61%
.
On the news, recently, WuXi PharmaTech publicly disclosed the 2021 semi-annual performance report
.
During the reporting period, WuXi AppTec achieved revenue of 10.
537 billion yuan, a year-on-year increase of 45.
7%; net profit attributable to the parent was 2.
675 billion yuan, a year-on-year increase of 55.
79%
.
With the release of the company's performance growth announcement, securities institutions such as WuXi PharmaTech are optimistic about WuXi PharmaTech.
Among them, Haitong Securities released a research report saying that the prosperity of the CRO and CDMO industries continued to rise, and WuXi PharmaTech gave full play to the "integrated, end-to-end" R&D services.
The platform advantage, empowering customers in terms of capability and scale, is expected to achieve comprehensive growth across the entire line of business
.
Give WuXi AppTec an "Outperform" rating
.
According to the equity information of the Hong Kong Stock Exchange, WuXi PharmaTech was held by FIL Limited on August 24 at an average price of HK$1,495,733 per share to increase its holdings of 546,900 shares, involving a capital of approximately HK$81,801,600
.
After the increase in holdings, the latest number of shares held by FIL Limited is 27.
7021 million shares, and the shareholding ratio has increased from 6.
98% to 7.
12%
.
BeiGene rose more than 3% BeiGene rose 2.
52% as of press time, and is now at HK$183.
400, with a turnover of 59.
77 million and a turnover rate of 0.
03%.
The current total market value is 221 billion
.
On August 27, BeiGene released its first-half 2021 results announcement.
For the six months ended June 30, 2021, the company's total revenue increased by approximately 542.
2% to approximately US$756 million
.
Among them, product revenue increased by approximately 107.
9% to approximately US$245 million, and cooperation income increased to approximately US$511 million
.
Research and development expenses for the period increased 14.
7% to $677 million
.
During the reporting period, the company had about 50 drugs and drug candidates in the commercial stage or clinical development stage, including 10 approved drugs, 2 pending drugs and more than 30 drugs in clinical development stage
.
CITIC Securities issued an announcement saying that the company's products under development for many years have been listed one after another, and at the same time, it has opened up a broad market at home and abroad
.
The company's early R&D pipelines have large potential targets, and new products have been incorporated through commercial cooperation to enrich the R&D pipelines
.
It is expected that with the successive listing of new products, the company will usher in a period of explosive performance
.
The bank believes that the reasonable valuation of the company is about 40.
947 billion US dollars, corresponding to the target price of Hong Kong stocks of 261 Hong Kong dollars, and maintains a "buy" rating
.
Among them, Corning & Jereh Pharmaceutical-B rose by more than 11%.
In addition, WuXi AppTec, BeiGene and other stocks also rose significantly
.
Corning & Jereh Pharma-B rose more than 11% against the market in early trading.
Among them, Corning & Jereh Pharma-B rose more than 11% against the market in early trading
.
As of press time, it rose 9.
39% to HK$21.
20, with a turnover of HK$65.
55 million and a current total market value of 19.
512 billion
.
Not long ago, Corning Jerry Pharmaceutical released its 2021 performance report.
For the six months ended June 30, 2021, the company recorded other income of 22.
5 million yuan, and medium-term R&D expenses increased by 73.
5% year-on-year to 232 million yuan.
The main reasons include: : an increase in the number of ongoing clinical trials; an increase in the scale of clinical studies; the advancement of clinical trials of drug candidates; and an increase in staff costs due to an increase in R&D staff and the grant of options to staff resulting in increased compensation
.
During the reporting period, the company's KN046, KN035 and other drug product pipelines and business operations have made significant progress
.
Ping An Securities released a research report saying that the core products of Corning & Jereh Pharmaceuticals are progressing smoothly, and this year is expected to start the first year of commercialization
.
As the next generation of antibodies, double antibodies are expected to be able to solve some of the problems that are difficult for monoclonal antibodies and small molecules to solve
.
The industry believes that the company is expected to be able to deploy the market in advance and occupy the first-mover advantage
.
Under the good development prospects of the industry in which the company is located, based on the company's rich independent technology platform, there will still be a rich pipeline layout in the future, which is expected to further enhance the company's performance; coupled with the announcement of a number of clinical data in the second half of this year, it will catalyze the company's value Upgrade, Ping An Securities maintained the company's "recommended" rating
.
WuXi PharmaTech's rapid intraday rise On August 31, WuXi PharmaTech rose rapidly intraday, with an increase of more than 2% within 5 minutes.
As of press time, it was reported at 132.
21 yuan, with a turnover of 2.
062 billion and a turnover rate of 0.
61%
.
On the news, recently, WuXi PharmaTech publicly disclosed the 2021 semi-annual performance report
.
During the reporting period, WuXi AppTec achieved revenue of 10.
537 billion yuan, a year-on-year increase of 45.
7%; net profit attributable to the parent was 2.
675 billion yuan, a year-on-year increase of 55.
79%
.
With the release of the company's performance growth announcement, securities institutions such as WuXi PharmaTech are optimistic about WuXi PharmaTech.
Among them, Haitong Securities released a research report saying that the prosperity of the CRO and CDMO industries continued to rise, and WuXi PharmaTech gave full play to the "integrated, end-to-end" R&D services.
The platform advantage, empowering customers in terms of capability and scale, is expected to achieve comprehensive growth across the entire line of business
.
Give WuXi AppTec an "Outperform" rating
.
According to the equity information of the Hong Kong Stock Exchange, WuXi PharmaTech was held by FIL Limited on August 24 at an average price of HK$1,495,733 per share to increase its holdings of 546,900 shares, involving a capital of approximately HK$81,801,600
.
After the increase in holdings, the latest number of shares held by FIL Limited is 27.
7021 million shares, and the shareholding ratio has increased from 6.
98% to 7.
12%
.
BeiGene rose more than 3% BeiGene rose 2.
52% as of press time, and is now at HK$183.
400, with a turnover of 59.
77 million and a turnover rate of 0.
03%.
The current total market value is 221 billion
.
On August 27, BeiGene released its first-half 2021 results announcement.
For the six months ended June 30, 2021, the company's total revenue increased by approximately 542.
2% to approximately US$756 million
.
Among them, product revenue increased by approximately 107.
9% to approximately US$245 million, and cooperation income increased to approximately US$511 million
.
Research and development expenses for the period increased 14.
7% to $677 million
.
During the reporting period, the company had about 50 drugs and drug candidates in the commercial stage or clinical development stage, including 10 approved drugs, 2 pending drugs and more than 30 drugs in clinical development stage
.
CITIC Securities issued an announcement saying that the company's products under development for many years have been listed one after another, and at the same time, it has opened up a broad market at home and abroad
.
The company's early R&D pipelines have large potential targets, and new products have been incorporated through commercial cooperation to enrich the R&D pipelines
.
It is expected that with the successive listing of new products, the company will usher in a period of explosive performance
.
The bank believes that the reasonable valuation of the company is about 40.
947 billion US dollars, corresponding to the target price of Hong Kong stocks of 261 Hong Kong dollars, and maintains a "buy" rating
.
